Clinical Trials Logo

Filter by:
NCT ID: NCT00162357 Completed - Clinical trials for Diabetes Mellitus, Type 2

Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty

Start date: April 2004
Phase: Phase 4
Study type: Interventional

The purpose of this clinical research study is determine if patients with diabetes that have undergone previous opening of a heart blockage may have a blockage that is not causing any symptoms that may be detected by imaging with Cardiolite.

NCT ID: NCT00162240 Completed - Diabetes Mellitus Clinical Trials

PPAR - Combination With Metformin

Start date: June 2003
Phase: Phase 3
Study type: Interventional

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT ID: NCT00162175 Completed - Clinical trials for Metabolics Diabetes Nos

PPAR-COMBO With Sulfonylurea

Start date: July 2003
Phase: Phase 3
Study type: Interventional

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 in Combination with Glyburide Therapy in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sulfonylurea Therapy Alone.

NCT ID: NCT00157339 Completed - Asthma Clinical Trials

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Start date: August 2005
Phase: Phase 3
Study type: Interventional

Phase 3 , open-label, randomized study to evaluate the safety and efficacy of the Lilly/Alkermes inhaled insulin system compared to injected insulin in type 1 and type 2 diabetes patients with asthma or COPD. Patients will be treated for 12 months with a 2 month follow up period.

NCT ID: NCT00157157 Completed - Hemophilia A Clinical Trials

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Start date: April 1, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM) is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII (FVIII) before.

NCT ID: NCT00157040 Completed - Hemophilia A Clinical Trials

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Start date: June 7, 2002
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a pharmacokinetic evaluation, and Part 2 is an evaluation of efficacy and safety.

NCT ID: NCT00153816 Completed - Colorectal Cancer Clinical Trials

Vitamin D/Calcium Polyp Prevention Study

Start date: July 2004
Phase: Phase 2/Phase 3
Study type: Interventional

Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia. Building on their previous work, the investigators will investigate the chemopreventive effect of vitamin D in the large bowel, to study whether calcium with vitamin D is more effective than calcium alone, and to confirm their positive finding regarding calcium. The goal of this study is the development of chemopreventive combinations that will reduce risk of colorectal neoplasia sufficiently to permit the lengthening of surveillance intervals in most patients and to clarify important issues regarding the mechanisms of colorectal carcinogenesis and chemoprevention.

NCT ID: NCT00153101 Completed - Clinical trials for Cardiovascular Diseases

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Start date: November 2001
Phase: Phase 4
Study type: Interventional

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.

NCT ID: NCT00144846 Completed - Asthma Clinical Trials

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

Start date: September 2004
Phase: Phase 3
Study type: Interventional

This study evaluates the effect of cumulative dose administration of albuterol sulfate inhalation aerosol delivered with valved holding chamber and facemask. This is a four week study in birth to 23 month old subjects who are experiencing acute wheezing due to obstructive airways disease.

NCT ID: NCT00143611 Completed - Sepsis Clinical Trials

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.